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Abstract
Context: There is no consensus on the vitamin D status of children and adolescents with inflammatory bowel disease (IBD).
Aim: To determine the vitamin D status of patients with IBD by comparing their serum 25(OH)D concentration to that of
healthy controls.
Hypothesis: Serum 25(OH)D concentration will be lower in patients with IBD compared to controls.
Subjects and Methods: A case-controlled retrospective study of subjects with IBD (n = 58) of 2–20 years (male n= 31, age
16.3862.21 years; female n = 27, age16.5662.08 years) and healthy controls (n = 116; male n= 49, age 13.9064.59 years;
female n= 67, age 15.0464.12years). Study subject inclusion criteria: diagnosis of Crohn’s disease (CD) or ulcerative colitis
(UC). Vitamin D deficiency was defined as 25(OH)D of (,20 ng/mL) (,50 nmol/L), overweight as BMI of $85th but ,95th
percentile, and obesity as BMI $95th percentile. Data were expressed as mean 6 SD.
Results: Patients with CD, UC, and their controls had mean serum 25(OH)D concentrations of 61.69624.43 nmol/L,
53.26625.51, and 65.32627.97 respectively (ANOVA, p= 0.196). The overweight/obese controls had significantly lower
25(OH)D concentration compared to the normal-weight controls (p = 0.031); whereas 25(OH)D concentration was similar
between the normal-weight and overweight/obese IBD patients (p = 0.883). There was no difference in 25(OH)D between
patients with UC and CD, or between subjects with active IBD and controls. However, IBD subjects with elevated ESR had
significantly lower 25(OH)D than IBD subjects with normal ESR (p = 0.025), as well as controls (65.3628.0 nmol/L vs.
49.5625.23, p = 0.045).
Conclusion: There is no difference in mean serum 25(OH)D concentration between children and adolescents with IBD and
controls. However, IBD subjects with elevated ESR have significantly lower 25(OH)D than controls. Therefore, IBD subjects
with elevated ESR should be monitored for vitamin D deficiency.
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Introduction
There is no consensus on the vitamin D status of children and
adolescents with inflammatory bowel disease (IBD).The composite
term IBD refers to two diseases, Crohn’s disease (CD) and
ulcerative colitis (UC), which are characterized by chronic
inflammation of the gastrointestinal tract, marked by recurrent
periods of remission and exacerbation [1]. Pediatric CD is
characterized by discontinuous, transmural inflammation of the
gastrointestinal tract with preferential involvement of the ileo-
colonic segment, while UC is characterized by a more superficial,
continuous inflammation that extends proximally from the rectum
to variable areas of the large intestine [1].
Prolonged vitamin D deficiency could lead to poor health, as
strong associations between vitamin D deficiency and increased
risk for several diseases such as type 1 and type 2 diabetes,
cardiovascular diseases, rheumatoid arthritis, infectious diseases,
depression, and cancers of the breast, prostate, colon, and
pancreas, have been reported [2–4]. Though there is an ongoing
debate on the significance of these extra-skeletal functions of
vitamin D in humans [5,6], there is a universal consensus on its
skeletal functions, as vitamin D has been demonstrated to be vital
for bone mineralization, maintenance of bone strength, and the
prevention of fractures and consequent immobilization [6,7].
The lack of consensus on the vitamin D status of children and
adolescents with IBD stems from two primary reasons: first, the
studies that investigated the vitamin D status of children and
adolescents with IBD [8–12] focused primarily on determining the
prevalence of vitamin D deficiency in IBD, and secondarily on
comparing the vitamin D status of patients with the subtypes of
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IBD, i.e., UC and CD, but failed to compare their results directly
to a local control group of healthy children and adolescents.
Secondly, only one study has directly compared the vitamin D
status of children and adolescents with IBD to the vitamin D status
of age- and gender-matched peers [13]. This cross-sectional study
of 60 children with newly-diagnosed IBD and 56 controls found
that 25(OH)D level was significantly lower in children with IBD
compared to the controls. However, no subsequent studies have
been performed to confirm these findings. Furthermore, to our
knowledge, there has been no case-controlled study examining the
vitamin D status of patients with established IBD of more than one
year duration. This lack of clarity on the vitamin D status of
children and adolescents with IBD compared to their peers has
made it difficult to propose a coherent recommendation for
vitamin D supplementation in patients with IBD [9,14].
We designed this study to explore the hypothesis that serum
25(OH)D concentration is significantly lower in patients with IBD
compared to controls. The primary aim of this study was to
characterize the vitamin D status of patients with IBD by directly
comparing their mean serum 25(OH)D concentration to that of a
local group of healthy children.
Materials and Methods
Ethics statement
The study protocol was approved by the University of
Massachusetts Institutional Review Board. All patient records
and information were anonymized and de-identified prior to
analysis.
Subjects
All data were sourced from the Children’s Medical Center
Database of the UMassMemorial Medical Center, Worcester,
Massachusetts, USA. The medical records of children and
adolescents of ages 2–20 years with a confirmed diagnosis of
Crohn’s disease or ulcerative colitis from January 1, 2007 through
June 30, 2013, were reviewed. Study subjects (n = 58; 31 males)
were included if they had a diagnosis of Crohn’s disease or
ulcerative colitis. Subjects’ height, weight, gender, race, IBD
diagnosis, date of endoscopic IBD diagnosis, and any history of
vitamin D supplementation were recorded.
A group of healthy peers served as controls. The controls were
identified from the same database as the subjects. Subjects were
included in the control group (n= 116; 49 males) if they carried no
diagnosis of Crohn’s disease or ulcerative colitis. Subjects’ height,
weight, gender, race, and history of vitamin D supplementation
were similarly recorded.
Patients were excluded from this study if they carried a
concurrent diagnosis of any disease that affects calcium or vitamin
D metabolism. Subjects with a malabsorption syndrome, other
than IBD, were excluded. Further exclusion criteria included
patients with a history of vitamin D or calcium supplementation
prior to the date of 25(OH)D measurement, subjects on
continuous doses of oral corticosteroids for the management of
any disease other than IBD, pregnant or lactating subjects, and
patients with chronic liver disease.
We identified 76 children and adolescents of ages 2–20 years
with a diagnosis of IBD. Eighteen subjects were excluded based on
the above exclusion criteria. Fifty-eight subjects were included in
the study. The control group consisted of 116 non-IBD peers who
were randomly drawn from the same database using a systematic
sampling scheme. For this method, we alphabetized the list of
control patients then selected every 5th patient for inclusion in our
control group, thereby preserving randomization.
The ages of both the study subjects and their controls were
determined by the date of 25(OH)D measurement. The duration
of disease was designated as the interval from the date of
endoscopic diagnosis of IBD to the date of 25(OH)D measure-
ment. The percentages of subjects from the various ethnic/racial
groups for the control group were as follows: Non-Hispanic 75%,
African American 8%, White Hispanic 5%, Multi-ethnicity 5%,
Unknown 4%. Similarly, the percentages from the various ethnic/
racial groups for the IBD groups were: Non-Hispanic white 85%,
African American 3%, White Hispanic 3%, Multi-ethnicity 3%,
Unknown 5%.
Because vitamin D status varies with sunlight exposure and the
seasons, we categorized each subject’s date of vitamin D draw
according to the seasons as follows: fall (September 22–December
21), winter (December 22–March 21), spring (March 22–June 21),
and summer (June 22–September 21)[15].
Anthropometry
Height was measured to the nearest 0.1 cm using a wall-
mounted stadiometer (Holtain Ltd, Crymych, Dyfed, UK) that
was calibrated daily. Weight was measured to the nearest 0.1 kg
using an upright scale. BMI was derived using the formula weight/
height2 (kg/m2), and expressed as standard deviation score (SDS)
for age and gender based on National Center for Health Statistics
(NCHS) data [16]. Overweight was defined as BMI of $85th but
,95th percentile, while obesity was defined as a BMI of $95th
percentile for age and gender.
Assay
Serum 25(OH)D concentration was analyzed using 25-hydroxy
chemiluminescent immunoassay (DiaSorin Liaison; Stillwater,
Minnesota), which has a 100% cross-reactivity with both
metabolites of 25(OH)D namely, 25(OH)D2 and 25(OH)D3 and
thus measures total serum 25(OH)D content. Its functional
sensitivity is 10 nmol/L, and its intra- and inter-assay coefficients
of variation are 5% and 8.2%, respectively. Vitamin D status was
defined using 25(OH)D values based on criteria by The Endocrine
Society Clinical Practice Guideline as follows: vitamin D
deficiency,20 ng/mL (50 nmol/L), insufficiency 20–29.9 ng/
mL (50–74.5 nmol/L), and sufficiency$30 ng/mL (75 nmol/
L)[5], which is similar to the classification of vitamin D status by
the American Academy of Pediatrics and the Institutes of
Medicine criteria which denote vitamin D deficiency as
25(OH)D ,50 nmol/L; and sufficiency as 25(OH)D .50 nmol/
L [6,17].
Statistical analyses
Statistical analyses were performed using the SPSS Predictive
Analytics SoftWare v.21 (IBM Corporation, Armonk, NY) and
Microsoft Excel (2007). Means and standard deviations were
calculated for descriptive summary statistics and 25(OH)D
measurements. Multivariate and univariate comparisons on
anthropometrics, 25(OH)D, and other variables were conducted
using ANOVA and two-tailed student’s t-test respectively.
Specifically, ANOVA was used to compare the differences in the
parameters of interests between the controls, UC, and CD
subjects. Height, weight, and BMI data were expressed as z-
scores. Race, gender proportionality, and seasons of blood draw
were compared using Fisher’s exact test. Data were expressed as
mean 6 standard deviation (SD).
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Figure 1. Box plots of the comparison of 25-hydroxyvitamin D concentration of patients with inflammatory bowel disease (IBD)
and normal controls stratified by body mass index. This figure shows that the overweight/obese controls had significantly lower value for
25(OH)D than the normal weight controls (58.32627.63 vs. 69.76627.45, p = 0.031), while there was no significant difference in 25(OH)D value
between the normal weight and overweight/obese IBD patients (59.71626.44 vs. 60.91623.26, p = 0.883). Note: 50 nmol/L = 20 ng/mL.
doi:10.1371/journal.pone.0101583.g001
Figure 2. Scatterplot of the comparison of the 25-hydroxyvitamin D concentration and the duration of disease in inflammatory
bowel disease. This figure shows a non-significant positive relationship between serum 25(OH)D concentration and the duration of disease
(r2 = 0.054, b= 0.23, p = 0.08).
doi:10.1371/journal.pone.0101583.g002
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Results
Comparative analysis of the characteristics of subjects
with UC, CD, and their controls
Table 1 shows the analysis of the characteristics of the subjects
with UC, CD, and controls using a one-way ANOVA. The
controls were younger, had higher value for weight SDS, and a
higher prevalence of overweight/obese status compared to the UC
and CD groups. There was no difference in mean serum 25(OH)D
concentration (p = 0.196) between the groups. There was a non-
significantly higher prevalence of vitamin D deficiency as defined
by a 25(OH)D value of ,50 nmol/L (20 ng/mL) in both the UC
and CD compared to controls (p = 0.070).
Comparison of the characteristics of the subjects with UC
vs. CD
When the IBD cohort was stratified by IBD sub-types, UC vs.
CD, there were no significant differences in age, gender, weight,
BMI, disease duration, or season of vitamin D measurement.
Subjects with CD were non-significantly shorter than the UC
patients (p = 0.05). There was no difference in mean serum
25(OH)D concentration between groups (53.3625.4 vs.
61.8624.4, p= 0.24). Subjects with UC had a non-significantly
higher prevalence of vitamin D deficiency compared to the CD
subjects (50% vs. 40%, p= 0.53).
The effect of adiposity on serum 25(OH)D in IBD vs.
controls
To investigate the effect of adiposity on 25(OH)D concentration
in IBD vs. controls, the subjects were stratified into normal-weight
vs. overweight/obese groups (Figure 1). The overweight/obese
controls had significantly lower 25(OH)D concentration compared
to the normal-weight controls (p = 0.031), whereas 25(OH)D
concentration was similar between the normal-weight and
overweight/obese IBD patients (p = 0.883). Further stratification
of the IBD cohort into UC and CD showed no difference in
25(OH)D concentration between the normal-weight and over-
weight/obese groups for CD (p= 0.98) or UC (p= 0.70). These
data suggest that adiposity has no effect on serum 25(OH)D
concentration of patients with IBD.
The relationship between the duration of IBD and serum
25(OH)D concentration
We first compared the mean 25(OH)D concentration of the
control group to 13 patients with IBD who had serum 25(OH)D
estimation at the time of diagnosis of IBD, i.e. during active
disease, and found no significant difference in their mean
25(OH)D concentration (65.3628.0 vs. 63.8630.1 nmol/L,
p = 0.86). Next, we investigated the relationship between the
duration of disease and serum concentration of 25(OH)D
(Figure 2). There was a non-significant, positive relationship
between serum 25(OH)D concentration and the duration of
disease (r2 = 0.054, b=0.23, p = 0.08).
The relationship between the severity of IBD and serum
25(OH)D concentration
Using the Pediatric Crohn’s Disease Activity Index
(PCDAI)[18] and Lichtiger Colitis Activity Index (LCAI)[19], to
quantify the severity of IBD, we investigated the differences in
serum 25(OH)D concentration in the three groups: controls,
n = 116; quiescent IBD cases n= 22; active IBD cases n= 8. There
was no difference in serum 25(OH)D concentration between three
groups: [controls, 65.3627.7 nmol/L; quiescent IBD cases
61.3628.3; active IBD cases 54.5622.5, ANOVA p =0.498.
Post hoc comparisons detected no significant difference in
25(OH)D levels between the groups.
We then stratified the IBD cohort using ESR as a marker of
inflammation and compared their serum 25(OH)D level to the
controls. Within the IBD cohort, serum 25(OH)D concentration
was significantly lower in patients with elevated ESR levels (ESR
of .21 mm/hr) compared to those with normal ESR values
(49.5625.2 nmol/L vs. 65.6622.1, p = 0.025).
Subsequent analysis of the mean serum 25(OH)D concentra-
tions of the 3 groups: controls (n = 116), IBD with elevated ESR
(n= 19), and IBD with normal ESR (n= 37), showed a near-
significant difference in 25(OH)D between the groups (ANOVA
p=0.052). Post hoc comparisons showed a significant difference in
25(OH)D concentration between the controls and IBD subjects
with elevated ESR (65.3628.0 nmol/L vs. 49.54625.23,
p = 0.045), but not between the controls and the IBD subjects
with normal ESR (65.3628.0 vs. 65.6622.1, p = 0.998).
Discussion
This study found no significant difference in the serum
concentration of 25(OH)D in children and adolescents with IBD
compared to normal controls. The normal-weight controls had
significantly higher 25(OH)D concentration compared to the
overweight/obese controls as well as the normal-weight IBD
subjects. There was no difference in 25(OH)D between the
normal-weight IBD and the overweight/obese IBD subjects. In
contrast, subjects with IBD and elevated ESR had significantly
lower serum 25(OH)D concentration compared to the healthy
controls, and subjects with IBD and normal ESR level.
This is the second study to directly compare the vitamin D
status of children and adolescents with IBD to healthy controls.
Our finding, however, is contrary to the report by El-Matary et al
[13] who described lower 25(OH)D concentration in a cross-
sectional study of children with newly-diagnosed IBD compared to
controls. Our report differed from the above-referenced study in
that our study included subjects with more established IBD, with
mean disease duration of thirty-two months. However, our sub-
analysis found no difference in the mean 25(OH)D concentration
measure at the time of IBD diagnosis compared to the mean
25(OH)D of the controls. Thus, this study found no evidence for
subnormal vitamin D status in patients with newly-diagnosed IBD
compared to controls in our cohort.
This study’s findings on the 25(OH)D levels of established IBD
are consistent with the report of a case-controlled study that
reported no significant difference in serum 25(OH)D in adult
patients with established IBD [20].
The effect of disease duration on vitamin D deficiency is
unclear, as some studies report longer disease duration as a risk
factor for vitamin D deficiency [20], while others found a positive
correlation between disease duration and serum 25(OH)D
concentration [8]. This study’s findings are in agreement with
the above report of a positive relationship between disease
duration in IBD and 25(OH)D concentration (Figure 2). One
explanation for this association is that the initiation of treatment in
patients with IBD results in some degree of healing of the mucosal
damage and consequent improvement in the absorption of vitamin
D. It is also possible that the phenomenon of compensation which
has been described in celiac disease, also occurs in IBD and leads
to increased vitamin D absorptive capacity by the unaffected
mucosal surfaces [21].
Additional case-controlled studies are warranted to accurately
characterize the vitamin D status of patients with IBD at various
The Vitamin D Status in Inflammatory Bowel Disease
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phases of the disease. This is necessary because the other studies
that have examined the vitamin D status of patients with IBD
lacked control groups, focused primarily on either the prevalence
rate of vitamin D deficiency in IBD, or limited their comparison of
vitamin D status to patients with the subtypes of IBD, i.e., UC and
CD. For example, one study found normal 25(OH)D concentra-
tion in children with CD [12], while another study reported lower
25(OH)D concentration in children with CD compared to those
with UC, even though the mean 25(OH)D concentration was
normal for the two IBD sub-types [11]. Two studies that defined
vitamin D deficiency using a cut-off value of 37.4 nmol/L (15 ng/
mL) reported prevalence rates of 16% for children with CD [10]
and 10.8% for children and adolescents with IBD [8]. Three
studies have investigated the vitamin D status of children and
adolescents using a 25(OH)D cut-off value of 50 nmol/L (20 ng/
mL), similar to the current study. The first of these studies which
was conducted in Australia [22] reported a 19% prevalence of
vitamin D deficiency while the other two studies from the same
center in New England, USA, reported prevalence rates of 34.6%
[8] and 14.3%[9]. A similar study in healthy adolescents in New
England that used a cut-off value of 50 nmol/L to define vitamin
D deficiency reported a prevalence of 42.0% [23]. An analysis of
the prevalence of vitamin D deficiency in the subtypes of IBD
detected no significant differences between UC and CD at
25(OH)D cut-off values of 38 nmol/L or 50 nmol/L [8]. Thus,
the results of studies investigating the vitamin D status of children
and adolescents with IBD are limited and discordant.
Though the studies that characterized the prevalence of vitamin
D deficiency in IBD have provided important information in this
field, they have not proven that vitamin D deficiency is a feature of
IBD as they did not compare their vitamin D data to those of
healthy children and adolescents in a case-controlled research
design. This is expressed in a recent call for more studies
comparing the vitamin D status of patients with IBD to those of
healthy controls [9].
The lack of a demonstration of subnormal vitamin D status in
IBD compared to controls may be explained by the fact that in
addition to oral intake, this prohormone is synthesized in the skin
through exposure to ultra-violet radiation. Hence, dietary intake of
vitamin D is not necessarily required to maintain normal vitamin
D status in individuals who maintain adequate exposure to
sunlight.
There was neither a significant difference in serum 25(OH)D
concentration between IBD subjects and controls, nor between
IBD subjects with active vs. quiescent disease.
In contrast, IBD subjects with elevated ESR had significantly
lower 25(OH)D concentration than IBD subjects with normal
ESR values. When compared to controls, subjects with IBD and
normal ESR level had similar 25(OH)D concentration as controls,
whereas subjects with IBD and elevated ESR had significantly
lower 25(OH)D than controls (65.3628.0 nmol/L vs.
49.54625.23, p = 0.045). This finding supports previous reports
of an independent association between ESR and lower 25(OH)D
concentration in IBD [8,14]. However, to the best of our
knowledge, this is the first study to report significantly lower
25(OH)D concentration in patients with IBD and elevated ESR
compared to healthy controls.
Adiposity and 25-hydroxyvitamin D
Obesity occurs in IBD despite the strong association between
IBD and growth retardation [24]. A recent study of nearly 1600
children reported an obesity rate of 20% in children with IBD; and
a rate for overweight status that is similar to that of the general
population at nearly 30% [25]. The control group in this study
had a non-significantly higher BMI z-score than the subjects with
IBD. To determine the effect of adiposity on 25(OH)D concen-
tration, we stratified the subjects and controls into normal-weight
and overweight/obese groups based on BMI criteria(Figure 1).
Even though there was no difference in mean serum 25(OH)D
between the IBD patients and controls (Table 1), upon stratifica-
tion into BMI sub-groups, the normal-weight controls had
significantly higher 25(OH)D concentration compared to the
overweight/obese IBD patients (p = 0.031). In contrast, serum
25(OH)D concentration was similar between the normal-weight
IBD and the overweight/obese IBD patients (p = 0.883). The
normal-weight controls had significantly higher 25(OH)D concen-
tration compared to the normal-weight IBD subjects (p = 0.023),
but there was neither a difference in serum 25(OH)D concentra-
tion between the overweight/obese controls vs. the overweight/
obese IBD subjects, nor between normal-weight IBD vs.
overweight/obese IBD.
We and others have shown that increased adiposity is associated
with vitamin D deficiency [26,27]. The mechanism of this
association is unclear, however, proposed causative factors include
poor nutrition, inadequate exposure to sunlight, and the seques-
tration of vitamin D in fat stores in overweight/obese individuals
[28]. Interestingly, adiposity had no effect on the vitamin D status
of our IBD cohort. More research is needed to determine the
adiposity threshold necessary to induce significant reduction in
serum 25(OH)D concentration [9] through processes such as the
sequestration of vitamin D in fat stores in patients with IBD [28].
Strengths and limitations
This study has some limitations. First, the cross-sectional study
design limits causal inference on the effects of seasons, race, and
adiposity on vitamin D status. Second, we did not administer a
food-recall to accurately determine dietary vitamin D intake.
Third, we did not exhaustively evaluate the components of the
complex vitamin D metabolic pathway, such as parathyroid
hormone (PTH), 1,25-dihydroxyvitamin D, 24,25-dihydroxyvita-
min D, and vitamin D receptor activity. This is important because
PTH could be elevated in states of vitamin D deficiency and
hypocalcemia, while 24,25-dihyroxyvitamin D could be elevated
in states on increased vitamin D degradation. However, 25(OH)D
is the major circulation form of vitamin D and its stability in
plasma, and a long half-life of .15 days makes it a highly sensitive
and specific marker of vitamin D status [29]. Fourth, our control
group was younger than the IBD cohort: such a difference could
potentially influence our results, however, earlier studies found no
relationship between age and 25(OH)D concentration in children
and adolescents with IBD [8,13]. Fifth, we did not adjust for the
effect of pubertal maturation on 25(OH)D concentration, howev-
er, others have shown that pubertal maturation does not influence
vitamin D concentration in IBD [30]. Finally, our results were
derived from a single tertiary care center in the northern United
States located at latitude 42uN. Therefore, we are uncertain that
our results are generalizable to other centers, countries, and
geographical latitudes.
The unique strength of this study is its case-controlled design
which enabled us to evaluate a large cohort of patients with IBD
and compare their results to a control group. This large sample
size enabled us to detect subtle differences between the groups of
interest. Our sample contained a fair representation of the
fractional composition of each of the major racial groups in
Central Massachusetts, thus enabling us to analyze the effects of
differential insolation on racial groups. The control group was
randomly selected using a structured randomization scheme. This
study was conducted exclusively amongst subjects living in the
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same geographical latitude (42uN), thus ensuring uniformity of
exposure to solar radiation. Phlebotomy was performed at
different seasons of the year, thus ensuring that seasonality did
not confound our results. Furthermore, the relationship between
duration of IBD and 25(OH)D was analyzed, and effect of disease
severity on 25(OH)D concentration in IBD was analyzed and
compared to controls. All anthropometric data were expressed as
z-score, and the analyses were adjusted for covariates.
Conclusions
There was no difference in mean serum 25(OH)D concentra-
tion between children and adolescents with IBD and controls. IBD
subjects with elevated ESR had significantly lower serum
25(OH)D concentration compared to the healthy controls, and
subjects with IBD and normal ESR level. This finding of vitamin
D deficiency in subjects with IBD and elevated ESR suggests that
inflammation is a risk factor for vitamin D deficiency in IBD.
Therefore, it may be prudent to closely monitor patients with IBD
and elevated ESR for vitamin D deficiency.
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